Scarica l'app Stockscreener
1.1485
4.01%
-0.0391
Precedente Chiudi:
$1.1876
Aprire:
$1.21
Volume 24 ore:
205.37K
Relative Volume:
0.34
Capitalizzazione di mercato:
$33.87M
Reddito:
-
Utile/perdita netta:
$-10.21M
Rapporto P/E:
-1.9659
EPS:
-0.5842
Flusso di cassa netto:
-
1 W Prestazione:
-4.20%
1M Prestazione:
+8.71%
6M Prestazione:
-33.72%
1 anno Prestazione:
+9.62%
Intervallo 1D:
$1.10
$1.23
Intervallo di 1 settimana:
$1.07
$1.24
Portata 52W:
$0.81
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Nome
Neurosense Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.1403 | 35.64M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.17 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.87 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.00 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.20 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.54 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie
Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser
How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks
Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView
Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser
How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser
Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ
Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt
Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World
NeuroSense Gains FDA Approval for Phase 3 ALS Trial - MSN
Prepare Yourself for Liftoff: NeuroSense Therapeutics Ltd (NRSN) - Setenews
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense receives FDA clearance to initiate pivotal phase 3 trial for PrimeC in ALS - marketscreener.com
NeuroSense Therapeutics (NRSN) Maintains 'Buy' Rating and $14 Ta - GuruFocus
NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS - marketscreener.com
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - Barchart.com
NeuroSense (Nasdaq: NRSN) to start pivotal Phase 3 PARAGON trial of PrimeC in ALS - Stock Titan
NeuroSense Therapeutics Ltd. (NRSN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can NeuroSense Therapeutics Ltd. (H1Z) stock ride next bull market cyclePortfolio Value Summary & AI Forecasted Stock Moves - newser.com
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - TipRanks
Can NeuroSense Therapeutics Ltd. stock hit analyst price targetsQuarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - newser.com
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
Is NeuroSense Therapeutics Ltd. (H1Z) stock a safe buy pre earningsWatch List & Consistent Growth Equity Picks - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock beat revenue estimatesDip Buying & Free Reliable Trade Execution Plans - newser.com
How strong dollar benefits NeuroSense Therapeutics Ltd. (H1Z) stockJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Using RSI to spot recovery in NeuroSense Therapeutics Ltd.IPO Watch & Weekly Top Stock Performers List - newser.com
What risks investors should watch in NeuroSense Therapeutics Ltd. Equity Warrant stockQuarterly Portfolio Review & Low Volatility Stock Suggestions - newser.com
Why NeuroSense Therapeutics Ltd. stock is in analyst buy zoneJuly 2025 Retail & Free Safe Entry Trade Signal Reports - newser.com
Key metrics from NeuroSense Therapeutics Ltd. Equity Warrant’s quarterly data2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
What sentiment indicators say about NeuroSense Therapeutics Ltd. stockQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com
Is NeuroSense Therapeutics Ltd. stock a bargain at current levels - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock sustain uptrend momentumWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
NeuroSense Bets On Breakthrough ALS And Alzheimer’s Treatments - Finimize
Signal strength of NeuroSense Therapeutics Ltd. stock in tech scannersFed Meeting & AI Powered Buy and Sell Recommendations - newser.com
NeuroSense Therapeutics Ltd (NRSN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Neurosense Therapeutics Ltd Azioni (NRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.77%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):